Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions develops and supplies public health products and medical countermeasures for government agencies, healthcare providers, and community preparedness programs. Its news centers on products such as NARCAN® Nasal Spray for opioid overdose emergencies and ACAM2000® for smallpox and mpox, along with biodefense countermeasures for threats including anthrax, botulism, and Ebola.
Recurring updates also cover quarterly results, debt refinancing and balance-sheet actions, regulatory approvals, government supply activity, and manufacturing services. The company reports on bioservices agreements and facility utilization at sites such as Canton, Massachusetts, and Winnipeg, Manitoba, where it supports vaccine, biologic, and drug product manufacturing programs.
Emergent BioSolutions (NYSE: EBS) announced participation in two key virtual investor conferences in June 2020. The events include the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on June 23, featuring a fireside chat at 3:00 PM Eastern, and the Three Part Advisors Virtual East Coast IDEAS Investor Conference on June 24, offering a pre-recorded presentation available from 8:00 AM Eastern. The webcasts will cover recent business developments and financial guidance, accessible via the Emergent website.
Emergent BioSolutions (EBS) has signed an $87 million agreement to provide contract development and manufacturing services for AstraZeneca's COVID-19 vaccine, AZD1222. This partnership supports Operation Warp Speed, aiming to deliver a vaccine by January 2021. Emergent will utilize its Gaithersburg facility for development and its Baltimore Bayview facility for large-scale manufacturing, capable of producing tens to hundreds of millions of vaccine doses annually. The company plans to update its 2020 financial outlook in Q2 financial results.
The U.S. District Court for the District of New Jersey ruled in favor of Teva Pharmaceuticals in the patent litigation concerning NARCAN® Nasal Spray 4mg/spray. Emergent BioSolutions plans to appeal the decision to the Court of Appeals for the Federal Circuit. Doug White, a senior executive at Emergent, expressed disappointment but reaffirmed the company’s commitment to improve access to NARCAN® and aid in combating the opioid crisis. Emergent will update its 2020 financial outlook related to this case and its COVID-19 initiatives during the second quarter financial results announcement.
Emergent BioSolutions has expanded its partnership with HHS through a $628 million task order under its 2012 contract with BARDA. This task order supports rapid COVID-19 vaccine production, committing $542.7 million to CDMO services and $85.5 million for fill/finish capacity expansion. Emergent aims to strengthen the U.S.-based manufacturing supply chain for pharmaceutical innovators, leveraging its Baltimore Bayview facility's significant production capabilities. The company's long-standing relationship with the government highlights its key role in addressing public health needs.
Emergent BioSolutions announced its 2020 Annual Meeting of Stockholders will be held virtually on May 21, 2020, at 9:00 AM EDT due to the COVID-19 pandemic. Stockholders of record as of March 26, 2020, can participate by visiting the company’s virtual meeting site. Only those with a Control Number can ask questions; others can attend in listen-only mode. Detailed instructions for participation are provided, with a replay of the meeting available on the company’s website afterward. The company aims to protect public health and enhance life through its products and services.
Summary not available.